A comparison of the post-marketing safety of four selective serotonin re-uptake inhibitors including the investigation of symptoms occurring on withdrawal

British Journal of Clinical Pharmacology
J S PriceA V MacKay

Abstract

1. We have addressed the question of whether there is a 'serotonin withdrawal syndrome' by analysis of spontaneous reports of suspected adverse drug reactions (ADRs) associated with four SSRIs. A comparison of the post-marketing safety profiles of the four SSRIs has also been made. 2. The UK database of ADRs was examined for reactions associated with fluoxetine, fluvoxamine, paroxetine and sertraline. The safety profiles of the four SSRIs were similar. However, withdrawal reactions with paroxetine constitute a greater proportion of reports (5.1%) than with the other SSRIs (0.06-0.9%). They have been reported more often with paroxetine (0.3 reports per thousand prescriptions) than with sertraline and fluvoxamine (0.03), and least often with fluoxetine (0.002). 3. Descriptions of withdrawal reactions received and further details of 217 reports of withdrawal reaction with paroxetine obtained by mailing a questionnaire to the reporting doctor were examined. Withdrawal symptoms were diverse but most commonly comprised dizziness, paraesthesia, tremor, anxiety, nausea and palpitation. They usually occurred after 2 days and lasted for an average of 10 days. There was no evidence of a physical drug dependency syndrome. 4. Symptoms diffe...Continue Reading

Citations

Feb 6, 1999·Journal of Clinical Psychopharmacology·R C RosenM Menza
Nov 10, 1998·Journal of Psychopharmacology·P J Goodnick, B J Goldstein
May 29, 2000·The British Journal of Psychiatry : the Journal of Mental Science·D MichelsonR G Tepner
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Mace, D Taylor
May 12, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·P M Haddad
Jul 13, 2001·Journal of Psychopharmacology·P M HaddadS M Dursun
Jan 9, 2003·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Borwin BandelowUNKNOWN World Federation of Societies of Biological Psychiatry Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive
Dec 4, 2003·Expert Opinion on Pharmacotherapy·Michael Gitlin
Apr 16, 2004·Journal of Toxicology. Clinical Toxicology·I MoragE Heyman
Jan 1, 2009·Plastic and Reconstructive Surgery·Simon H ChinSherrell J Aston
Sep 17, 2008·Journal of Clinical Psychopharmacology·Giovanni PolimeniPlacido Bramanti
Nov 6, 2008·Expert Opinion on Drug Safety·Oleg V Tcheremissine
Apr 11, 2009·Homeopathy : the Journal of the Faculty of Homeopathy·Marcus Zulian Teixeira
Apr 8, 2010·Human Psychopharmacology·Samir Kumar PraharajSujit Sarkhel
Mar 1, 2009·International Clinical Psychopharmacology·David V Sheehan, Kunitoshi Kamijima
Jun 13, 2015·Journal of Clinical Psychopharmacology·David J Greenblatt
May 22, 2019·Journal of Psychopharmacology·Sameer JauharDavid J Nutt
May 22, 2019·BMJ : British Medical Journal·James DaviesAnne Guy
Oct 8, 1999·Journal of Psychopharmacology·P Haddad
May 15, 2002·Advances in Therapy·Lut Tamam, Nurgul Ozpoyraz
Sep 5, 2001·The British Journal of Psychiatry. Supplement·J Donoghue, T R Hylan
Jun 5, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Sherese Ali, Roumen Milev
Jan 31, 2007·Journal of Perinatology : Official Journal of the California Perinatal Association·A L PottsJ P Shenai
Apr 15, 2011·Psychiatry and Clinical Neurosciences·Norio Yasui-Furukori, Sunao Kaneko
Aug 12, 2014·Human Psychopharmacology·Brian H Harvey, Francois N Slabbert
Jan 1, 2001·International Journal of Psychiatry in Clinical Practice·K Demyttenaere
Aug 25, 2000·Journal of Psychopharmacology·P Haddad
May 5, 2001·Expert Opinion on Pharmacotherapy·B G Pollock
Feb 12, 2004·Journal of Psychopharmacology·Lut Tamam, Nurgul Ozpoyraz
Jul 9, 2005·Epidemiologia e psichiatria sociale·Peter M Haddad
Apr 2, 2003·Psychiatry and Clinical Neurosciences·Geoffrey K IsbisterIan M Whyte
Nov 6, 2008·Expert Opinion on Drug Safety·David M MarksChi-Un Pae
Jul 15, 2003·Human Psychopharmacology·Jean Dalery, Adriaan Honig
Nov 30, 2006·The Annals of Pharmacotherapy·Wende Wood, Adrienne Einarson
Jun 21, 2005·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Hedvig Nordeng, Olav Spigset
Feb 9, 2007·Expert Review of Neurotherapeutics·Chi-Un Pae, Ashwin A Patkar
Sep 28, 2004·CNS Spectrums·Borwin Bandelow, Eckart Rüther

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.